Literature DB >> 15157262

Window-period human immunodeficiency virus transmission to two recipients by an adolescent blood donor.

Ruby Phelps1, Kenneth Robbins, Thomas Liberti, Ana Machuca, German Leparc, Mary Chamberland, Marcia Kalish, Indira Hewlett, Thomas Folks, Lisa M Lee, Matthew McKenna.   

Abstract

BACKGROUND: Pooled NAT and donor screening have reduced the diagnostic window period for HIV in the blood donor population to approximately 10 to 15 days. This report describes two cases of transfusion-acquired HIV infection and verification of transmission from the donor to the recipients, and attempts to identify how the 18-year-old donor acquired her infection. STUDY DESIGN AND METHODS: After a repeat donor had a positive HIV test result, two recipients of the donor's previous donation were identified and tested. The donor and recipients were interviewed and blood samples were obtained for HIV DNA sequencing and phylogenetic analysis.
RESULTS: The two recipients had positive HIV test results. Phylogenetic analysis showed a high genetic similarity among the viruses (bootstrap 100%), consistent with transmission from the donor to the recipients. Four of five men with whom the donor had sexual contact during the critical time period when infection most likely occurred were located and tested; results were negative for HIV.
CONCLUSIONS: Pooled NAT of blood donations has not eliminated the window period for HIV identification during seroconversion.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15157262     DOI: 10.1111/j.1537-2995.2004.03364.x

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  10 in total

Review 1.  Current safety of the blood supply in the United States.

Authors:  Roger Y Dodd
Journal:  Int J Hematol       Date:  2004-11       Impact factor: 2.490

Review 2.  Evolution of recombinant factor VIII safety: KOGENATE and Kogenate FS/Bayer.

Authors:  Jeanne M Lusher; Inge Scharrer
Journal:  Int J Hematol       Date:  2009-11-03       Impact factor: 2.490

Review 3.  Factors in enhancing blood safety by nucleic acid technology testing for human immunodeficiency virus, hepatitis C virus and hepatitis B virus.

Authors:  Venkatakrishna Shyamala
Journal:  Asian J Transfus Sci       Date:  2014-01

4.  HIV Seroconversion in blood donors from the coordinating blood bank in the State of Pará.

Authors:  Andrea Silvestre Lobão Costa; Danielle Murici Brasiliense
Journal:  Rev Bras Hematol Hemoter       Date:  2011

5.  High specific infectivity of plasma virus from the pre-ramp-up and ramp-up stages of acute simian immunodeficiency virus infection.

Authors:  Zhong-Min Ma; Mars Stone; Mike Piatak; Becky Schweighardt; Nancy L Haigwood; David Montefiori; Jeffrey D Lifson; Michael P Busch; Christopher J Miller
Journal:  J Virol       Date:  2009-01-07       Impact factor: 5.103

6.  Transmission of human immunodeficiency virus infection by renal transplantation.

Authors:  P Mukhopadhyay; V Kumar; M Rathi; H S Kohli; V Jha; V Sakhuja
Journal:  Indian J Nephrol       Date:  2012-03

Review 7.  Protecting the blood supply from emerging pathogens: the role of pathogen inactivation.

Authors:  Jean Pierre Allain; Celso Bianco; Morris A Blajchman; Mark E Brecher; Michael Busch; David Leiby; Lily Lin; Susan Stramer
Journal:  Transfus Med Rev       Date:  2005-04

Review 8.  Computer-based blood donor screening: a status report.

Authors:  Louis M Katz; Paul D Cumming; Edward L Wallace
Journal:  Transfus Med Rev       Date:  2007-01

Review 9.  Near-infrared spectroscopy: promising diagnostic tool for viral infections.

Authors:  Akikazu Sakudo; Yoshikazu Suganuma; Takanori Kobayashi; Takashi Onodera; Kazuyoshi Ikuta
Journal:  Biochem Biophys Res Commun       Date:  2006-01-06       Impact factor: 3.575

10.  Amotosalen photochemical inactivation of severe acute respiratory syndrome coronavirus in human platelet concentrates.

Authors:  D Pinna; A Sampson-Johannes; M Clementi; G Poli; S Rossini; L Lin; E Vicenzi
Journal:  Transfus Med       Date:  2005-08       Impact factor: 2.019

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.